^
    4ms
    First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study. (PubMed, Signal Transduct Target Ther)
    Treatment-related adverse events of grade ≥3 occurred in 60.0% of patients; immune-mediated adverse events of any grade was observed in 42.2%, with the majority being grade 1 or 2. In conclusion, first-line tislelizumab and ociperlimab plus GemCis yielded clinically promising tumor response and survival outcomes in advanced BTC and were generally well tolerated without new safety signals.
    P2 data • Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    5ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, BeiGene | Trial completion date: Feb 2027 --> Mar 2026 | Trial primary completion date: Oct 2026 --> May 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    6ms
    AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer. (PubMed, Gynecol Oncol)
    In patients with R/M CC who had received prior chemotherapy, ociperlimab + tislelizumab has promising antitumor activity in both all-comers and PD-L1+ subgroup, supporting further investigation of immune-modulating agent combinations for R/M CC.
    Clinical • P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    9ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=430, Enrolling by invitation, BeiGene | N=300 --> 430
    Enrollment change
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    9ms
    BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=121, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2025 | Trial primary completion date: Dec 2026 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • alcestobart (LBL-007)
    1year
    BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=121, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • alcestobart (LBL-007)
    1year
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1/2, N=53, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Aug 2024
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1year
    AdvanTIG-205: Ociperlimab with Tislelizumab and Chemotherapy in Participants with Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=272, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1year
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, BeiGene | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=449, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, BeiGene | N=80 --> 53 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    over1year
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)